gene

TFR1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TFR1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

551Connections

1Hypotheses

1Analyses

50Outgoing

50Incoming

5Experiments

1Debates

Summary

TFR1 is a gene implicated in neurodegeneration research. Key relationships include: activates, therapeutic target, regulates. Associated with ALS, Aging, Als. Connected to 277 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	RMT
Full Name	TfR1 Bispecific Antibody Shuttle for CNS Delivery
Aliases	TFR1
Chromosome	3q29
Protein Type	Receptor
Target Class	Receptor
Function	Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake
Mechanism of Action	Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake
Primary Expression	Ubiquitous, highest in proliferating cells and erythroid precursors
Druggability	Low (0.44)
Clinical Stage	Approved
Pathways	Amyloid, Complement, Endocytosis, Oxidative Stress, Phagocytosis
UniProt ID	P02786
NCBI Gene ID	7037
Ensembl ID	ENSG00000149571
GeneCards	RMT
Human Protein Atlas	RMT
Associated Diseases	Als, Alzheimer, cancer, Dementia
Known Drugs/Compounds	iron-transferrin complex, paricalcitol, valproic acid
Interactions	ABCB1, ACSL4, ALOX12, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Magnetosonic-Triggered Transferrin Receptor Cluste
KG Connections	538 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: TFR1 — AlphaFold P02786 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

RMT-TfR1 Bispecific Antibody Shuttle for CNS Delivery

idea · 1317 words

→

TFR1 Gene

gene · 1625 words

→

Pathway Diagram

graph TD
    TFR1["TFR1"] -->|"associated"| neurodegeneration["neurodegeneration"]
    TFR1["TFR1"] -->|"interacts"| LRP1["LRP1"]
    TFR1["TFR1"] -->|"interacts"| CAV1["CAV1"]
    TFR1["TFR1"] -->|"interacts"| ABCB1["ABCB1"]
    TFR1["TFR1"] -->|"co discussed"| AQP4["AQP4"]
    TFR1["TFR1"] -->|"co discussed"| CAV1_1["CAV1"]
    LRP1_2["LRP1"] -->|"interacts"| TFR1["TFR1"]
    CAV1_3["CAV1"] -->|"interacts"| TFR1["TFR1"]
    ABCB1_4["ABCB1"] -->|"interacts"| TFR1["TFR1"]
    LRP1_5["LRP1"] -->|"co discussed"| TFR1["TFR1"]
    style TFR1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (348)

Target	Relation	Type	Str
iron-transferrin complex	binds	compound	0.95
iron uptake	mediates	process	0.95
Antisense Oligonucleotides	transports	drug	0.95
blood-brain barrier	expressed_in	cell_type	0.95
Blood-Brain Barrier Transport	mediates	process	0.95
neurons	expressed_in	cell_type	0.90
ASO	binds	drug	0.90
Ferroptosis	activates	pathway	0.90
Ferroptosis	involved_in	process	0.88
Neuron	expressed_in	cell_type	0.85
cancer progression	promotes	process	0.85
Ferroptosis	mediates	process	0.85
tumorigenesis	involved_in	process	0.85
Cancer	biomarker_for	disease	0.85
iron homeostasis	involved_in	process	0.85
transferrin_receptor	encodes	protein	0.80
Aging	activates	disease	0.75
Parkinson	activates	disease	0.75
Neurodegeneration	activates	disease	0.75
Tumor	therapeutic_target	disease	0.75
Alzheimer's Disease	involved_in	disease	0.70
Autophagy	activates	pathway	0.70
Ferroptosis	biomarker_for	pathway	0.70
Tumor	regulates	disease	0.65
Ms	therapeutic_target	disease	0.65
Ischemia	inhibits	disease	0.65
Cardiac	therapeutic_target	disease	0.65
Cardiac	biomarker_for	disease	0.65
Aging	therapeutic_target	disease	0.65
Ms	expressed_in	disease	0.65
Ms	associated_with	disease	0.65
Stroke	inhibits	disease	0.65
Alzheimer	treats	disease	0.65
Als	interacts_with	disease	0.65
Ms	activates	disease	0.65
Carcinoma	inhibits	disease	0.65
Depression	treats	disease	0.65
Tumor	activates	disease	0.65
Amyotrophic Lateral Sclerosis	activates	disease	0.65
Ischemia	activates	disease	0.65
Als	associated_with	disease	0.65
Senescence	activates	disease	0.65
Als	activates	disease	0.65
Ms	inhibits	disease	0.65
Synucleinopathy	activates	disease	0.65
Depression	inhibits	disease	0.65
Fibrosis	biomarker_for	disease	0.65
Ms	interacts_with	disease	0.65
ALS	biomarker_for	disease	0.65
Ischemia	causes	disease	0.65

Incoming (203)

Source	Relation	Type	Str
TXB2	binds	drug	0.95
Ferritin	binds	protein	0.90
Transferrin	binds	protein	0.90
BI-hTFR1	binds	protein	0.90
h-84808267	targets_gene	hypothesis	0.90
h-aa2d317c	targets_gene	hypothesis	0.90
GPX4	co_mentioned_with	gene	0.90
FERROPTOSIS	activates	gene	0.90
Chronic Cerebral Hypoperfusion	upregulates	process	0.85
h-aa2d317c	targets	hypothesis	0.80
h-84808267	targets	hypothesis	0.80
GPX4	activates	gene	0.80
SLC7A11	activates	gene	0.70
PARKINSON'S DISEASE	activates	gene	0.70
ABCB1	interacts_with	gene	0.65
CAV1	interacts_with	gene	0.65
LRP1	interacts_with	gene	0.65
SLC7A11	co_mentioned_with	gene	0.60
ACSL4	co_mentioned_with	gene	0.60
LC3	activates	gene	0.60
BECN1	activates	gene	0.60
AND	inhibits	gene	0.60
ALZHEIMER	treats	gene	0.60
ALZHEIMER'S DISEASE	treats	gene	0.60
GBA1	activates	gene	0.60
FERROPORTIN	transports	gene	0.60
JUN	regulates	gene	0.60
GPX4	associated_with	gene	0.60
APP/PS1	treats	gene	0.60
OXIDATIVE STRESS	treats	gene	0.60
FERROPTOSIS	treats	gene	0.60
AND	interacts_with	gene	0.60
RNA	transports	gene	0.60
MALAT1	transports	gene	0.60
LOX	inhibits	gene	0.60
ACSL4	inhibits	gene	0.60
XPC	regulates	gene	0.60
SRC	therapeutic_target	gene	0.60
GOT1	activates	gene	0.60
ACSL4	activates	gene	0.60
CAT	associated_with	gene	0.60
TFRC	expressed_in	gene	0.60
IREB2	activates	gene	0.60
TP53	activates	gene	0.60
ALOX12	activates	gene	0.60
PINK1	therapeutic_target	gene	0.60
TAU	inhibits	gene	0.60
IREB2	expressed_in	gene	0.60
P62	inhibits	gene	0.60
DMT1	expressed_in	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Magnetosonic-Triggered Transferrin Receptor Clustering	0.719	neurodegeneration	Blood-brain barrier transport mechanisms

Mentioning Analyses (1)

Scientific analyses that reference this entity

Blood-brain barrier transport mechanisms for antibody therapeutics

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.773

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
iPSC-derived endothelial cell iron uptake with RLS CSF exposure	exploratory	restless legs syndrome	0.900	0.00	iPSC-derived human endothelial	proposed	N/A
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
s:** - Compare uptake with/without magnetic particles using tight junc	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$120,000
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
AAV Serotype Comparison for LRRK2 Knockdown in PD	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease. [PMID:40425446]	Sehlin D, Hultqvist G, Michno W, Aguilar	J Prev Alzheimers Dis	2025	1
Effect of ferroptosis on chronic cerebral hypoperfusion in vascular dementia. [PMID:37709116]	Fu P, Chen Y, Wu M, Bao B, Yin X, Chen Z	Exp Neurol	2023	1
On Iron Metabolism and Its Regulation. [PMID:33925597]	Vogt AS, Arsiwala T, Mohsen M, Vogel M,	Int J Mol Sci	2021	1
Transferrin Receptor Is a Specific Ferroptosis Marker. [PMID:32160546]	Feng H, Schorpp K, Jin J, Yozwiak CE, Ho	Cell Rep	2020	1
Transferrin and transferrin receptors update. [PMID:29969719]	Kawabata H	Free Radic Biol Med	2019	1
Time- and dose-dependent effects of bacterial infection on iron metabolism, infl [PMID:41619877]	Lu Y, Zhang Y, Niu C	Comp Biochem Physiol A Mol Int	2026	0
Ayanin combats against barium sulphate nanoparticles induced hepatotoxicity via [PMID:41666660]	Zhu D, Lu Y, Jamil S, Ashfaq H, Al-Emam	J Trace Elem Med Biol	2026	0
Role of iron and TfR1 in the application of high‑dose ascorbate against pancreat [PMID:41789665]	Piotrowsky A, Leischner C, Schmieder H,	Oncol Rep	2026	0
Yangxin granules exert cardioprotective effects against acute myocardial infarct [PMID:41868900]	Huo G, Zhou Y, Wu Z, Sun S, Zhu G, Cheng	American journal of translatio	2026	0
Conformational dynamics study of TfR1 upon transferrin binding via NMA and MD si [PMID:41921418]	Zemmouche M, Falque G, Cadet F, Gardebie	Journal of molecular graphics	2026	0
[Effects of acupuncture on ferroptosis and ferritinophagy in cerebral ischemia-r [PMID:41839581]	Wang YF, Dong YS	Zhen ci yan jiu = Acupuncture	2026	0
The therapeutic potential of Piezo1 channel-mediated ferroptosis and its inhibit [PMID:41854751]	Nan K, Zhang L, Zhao Y, Yin S, Peng Y, H	Apoptosis : an international j	2026	0
The Role of Artemisinin and its Derivatives in Cancer Therapy via Ferroptosis: A [PMID:41833023]	Osmanlioglu Dag SR, Tatli Cankaya II, Oz	Anti-cancer agents in medicina	2026	0
Raccoon eyes [PMID:35789012]	Ning Junjie	Journal of Paediatrics and Chi	2023	0
The Trend of Immunotherapy Combined with Nanomedicine. [PMID:34789123]	Shigao Huang; Qi Zhao	Current medicinal chemistry	2022	0
Test-retest reliability for performance-based outcome measures among individuals [PMID:35123456]	["Sions J", "Donohoe M", "Beisheim-Ryan	BMC musculoskeletal disorders	2022	0
Interfacial Imide Polymerization of Functionalized Filled Microcapsule Templates [PMID:36234567]	["Wei Z", "Ma X", "Wang P", "Pan J"]	Nanomaterials (Basel, Switzerl	2022	0
The impact of COVID-19 and non-pharmaceutical interventions on energy returns wo [PMID:36567890]	["Saif-Alyousfi A", "Saha A"]	Sustainable cities and society	2021	0
Implications of relationships with family, friends, and neighbors for changes in [PMID:33245678]	["Fuller H"]	Journal of women & aging	2021	0
[Longitudinal Direct Closure of Mitral Anterior Leaflet Large Perforation for In [PMID:34876543]	Morizumi S, Enomoto Y, Ikeda K, Suzuki Y	Kyobu geka. The Japanese journ	2021	0

Debates (1)

Multi-agent debates referencing this entity

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi

closed · Rounds: 4 · Score: 0.91 · 2026-04-06